Insulin has been studied in 634 papers since 1980: 63 trials and 232 observational studies in people, 70 in animals, 12 in cells, 223 reviews; 256 in the past year. The newest story, Nov 15, 2026: “Exercise and insulin boosted galactose uptake in older men”.
Independent labs report increased senescence with insulin in human cells but decreased senescence in mice; other studies report decreased senescence in human cells or no clear effect in mice. Human trials report less postoperative delirium with intranasal insulin, while a trial reports impaired verbal episodic memory during insulin stimulation. Some papers declare ties to insulin developers.
358 findings in 234 papers from 1991 to 2026, 39 of them since April 2026
Independent labs found the same change in cells, mice and people. 158 independent labs in 45 countries; 200 trials, 8 about aging, 80 with no results posted.
“insulin use (HR 1.34, 95% CI, 1.08-1.66) were significant diabetes-related predictors of all clinical fractures.”
Cells, mice and humans: replicated by independent labs. Worms or flies: a single group.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
About aging: the drug’s trials about aging. The total counts its trials for every use.
No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
158 independent labs in 45 countries
24 findings against
200 trials, 8 about aging, 80 with no results posted
Insulin improves cognitive function in humans (scheduled for elective orthopaedic surgery or pancreatic surgery with general anaesthesia) (P < 0.001, P = 0.001).
“Insulin treatment significantly increased postoperative MMSE and MoCA-B scores in group I than in group S”
Human trialscheduled for elective orthopaedic surgery or pancreatic surgery with general anaesthesiaintranasal administration40 IU/400 μLfrom 5 minutes before anaesthesia induction until 3 days postoperativelyn = 140
Insulin showed no clear effect on cognitive function in humans (frail older adults with type 2 diabetes and HFpEF) (Montreal Cognitive Assessment 19.00 to 19.1 (P = 0.81)).
“19.00 ± 3.71 vs. 19.1 ± 3.56 (P = 0.81) in the insulin group”
Human trialfrail older adults with type 2 diabetes and HFpEF1 month
Insulin improves cognitive function (via olfactory and trigeminal pathways).
“intranasal insulin administration emerges as a promising non-invasive therapeutic approach that bypasses the blood-brain barrier via olfactory and trigeminal pathways, suggesting significant potential for cognitive enhancement”
Reviewvia olfactory and trigeminal pathwaysintranasal
Insulin improves cognitive function in patients with mild cognitive impairment and Alzheimer's disease.
“the administration of certain antidiabetic drugs, such as intranasal insulin, metformin, incretins and thiazolidinediones, can improve cognitive function and memory”
Reviewin patients with mild cognitive impairment and Alzheimer's diseaseintranasal
Insulin improves cognitive function in humans (measured by MMSE versus placebo) (SMD 1.11, 95% CI (0.87, 1.35)).
“Of these treatments, intranasal insulin 20 IU (ITSN20), glucagon-like peptide-1 (GLP-1), and dipeptidyl peptidase 4 inhibitor (DPP-4) were associated with significantly improved MMSE scores”
Reviewmeasured by MMSE versus placebointranasal20 IUn = 333
Insulin showed no clear effect on body weight in humans.
“INI treatment did not change HbA1c, weight, waist circumference or BMI (Fig. C, D), but fasting serum glucose decreased in DM-Placebo group (p = 0.03) (Supplementary Table A.2.).”
Human trial24 weeks with 24 weeks of follow-upn = 244
Insulin decreases IL-6 in humans (scheduled for elective orthopaedic surgery or pancreatic surgery with general anaesthesia) (P = 0.034, P = 0.044).
“inhibited postoperative IL-6 and S100-β levels in Group I compared to Group S (P = 0.034, P = 0.044, respectively)”
Human trialscheduled for elective orthopaedic surgery or pancreatic surgery with general anaesthesiaintranasal administrationserum40 IU/400 μLfrom 5 minutes before anaesthesia induction until 3 days postoperativelyn = 140
“Besides, the serum levels of IL-6, TNF-α and S100β at T2−5 in the insulin group were significantly lower than those of the control group (IL-6: mean difference at T2, −4.14, p = 0.036; T3, −3.84, p = 0.039; T4, −3.37, p = 0.013; T5, −2.57, p = 0.042”
Human trialintranasalserumstarting 2 days before surgery until 1 h before admission to the operating roomn = 61
Insulin decreases inflammation in humans (undergoing hip fracture surgery under general anesthesia) (P < 0.001).
“Serum IL-6 and CRP levels at T1 were lower in the insulin group compared to controls (P < 0.001)”
Human trialundergoing hip fracture surgery under general anesthesiaserum20 units in 0.5 mL twice dailybeginning two days preoperatively and continuing for five daysn = 92
Insulin decreases inflammation in humans (metabolic syndrome undergoing noncardiac surgery) (P < 0.05 and P < 0.001).
“Mean peripheral plasma concentration of TNF-α (P < 0.05) and CRP (P < 0.001) in the insulin group was significantly declined compared with the placebo group on D3 and D7.”
Human trialmetabolic syndrome undergoing noncardiac surgeryplasma40 IU7 days
“During follow-up, HbA1c and body weight diverged significantly, with higher levels observed in the COAD group.”
HumansNewly diagnosed type 2 diabetes after successful initial intensive treatment and treatment cessation; compared with combined oral antidiabetic drugs
Insulin decreases delirium duration in humans (aged ≤88 years).
“Participants aged ≤88 years demonstrated a significant reduction in delirium duration [insulin: 3.88 (2.87, 6.92) days vs control: 7.03 (4.67, 9.66) days, HR 0.34, CI 0.16–0.74; P = 0.006”
Insulin showed no clear effect on delirium duration in humans.
“In the primary ITT analyses, the median (IQR) days of delirium were 4.82 (2.93, 9.21) in the insulin arm and 6.79 (3.97, 9.76) in the control arm [Mann–Whitney U: P =.27, unadjusted hazard ratio (HR) 0.9; CI 0.57–1.43; P =.66, adjusted HR 0.7; CI 0.43–1.15; P =.16].”
Insulin showed no clear effect on delirium duration in humans (delirium) (4.8 vs 6.8 days (HR 0.7, 95% CI 0.43-1.15; P = .16)).
“Median delirium duration [days (IQR)] was 4.8 [2.9, 9.2] for intranasal insulin and 6.8 [4.0, 9.8] for the control (HR 0.7, 95% CI 0.43-1.15; P = .16).”
Human trialdeliriumlong-acting insulin20 IU twice dailyn = 97
“Participants in the intranasal insulin group had a shorter acute length of stay, median days (IQR) 7.93 (4.62, 14.48) for insulin and 12.91 (6.86, 16.79) for the control (HR 0.56, CI 0.35–0.89, P =.014).”
Studies link insulin with 89 measures, most often mortality (12 studies), postoperative delirium (8) and hypoglycemia (8).
Mortality
↑upin humans11↓downin humans1RR 3.37
12 studies
Insulin is associated with mortality in humans (type 2 diabetes; insulin alone) (RR 3.37, 95% CI 3.10 to 3.67).
“Insulin alone and combined with oral glucose-lowering medications or glucagon-like peptide-1 receptor agonists were associated with increased mortality”
Insulin is associated with mortality in humans (HR 0.75, 95% CI 0.67-0.84).
“All active therapies were associated with lower mortality compared with no observed therapy, including GLP-1RA/SGLT2i (HR 0.71, 95% CI 0.58-0.87), metformin (HR 0.60, 95% CI 0.55-0.66), and insulin (HR 0.75, 95% CI 0.67-0.84).”
HumansType 2 diabetes after isolated coronary artery bypass grafting; compared with no observed therapyn = 19,237
Insulin is linked with a higher risk of mortality in T2DM patients after COVID-19.
“After adjusting for sex, age, following factors were independently associated with increased long-term mortality in T2DM patients after COVID-19: older age, male sex, insulin therapy.”
Insulin is linked with a higher risk of mortality in humans (incident diabetic foot ulcer).
“Independent predictors of 1-year mortality included male sex, older age, hospital-acquired DFU, insulin, major amputation, cardiovascular disease, cancer, dementia, ESKD, and liver disease.”
Insulin is associated with postoperative delirium in humans (surgical patients with type 2 diabetes mellitus) (adjusted OR = 0.195, 95% CI: 0.036-0.826; incidence 10.7% versus 36.4% with saline).
“Intranasal insulin was associated with reduced POD risk in T2DM patients (adjusted OR = 0.195, 95% CI: 0.036-0.826, P = 0.035)”
Human trialsurgical patients with type 2 diabetes mellitusperioperativen = 50
Insulin lowers the risk of postoperative delirium in humans (undergoing hip fracture surgery under general anesthesia) (10.9% vs. 30.4%, P = 0.020).
“Patients treated with INI showed a significantly lower incidence of POD within the 5-day postoperative period (10.9% vs. 30.4%, P = 0.020).”
Human trialundergoing hip fracture surgery under general anesthesia20 units in 0.5 mL twice dailybeginning two days preoperatively and continuing for five daysn = 92
Insulin lowers the risk of postoperative delirium in humans (scheduled for elective orthopaedic surgery or pancreatic surgery with general anaesthesia) (10.9% vs 26.6%, P = 0.024).
“decreased the incidence of POD within the 3-day postoperative period in Group I than in Group S (10.9% vs 26.6%, P = 0.024)”
Human trialscheduled for elective orthopaedic surgery or pancreatic surgery with general anaesthesiaintranasal administration40 IU/400 μLfrom 5 minutes before anaesthesia induction until 3 days postoperativelyn = 140
Insulin lowers the risk of postoperative delirium in humans (undergoing joint replacement) (8.33% vs 23.23%, P=0.004).
“8 patients (8.33%) occurred POD in insulin group within 5 days after surgery, significantly fewer than 23 patients (23.23%) in placebo group (P=0.004).”
Human trialundergoing joint replacementtwice 40 IUn = 212
Insulin lowers the risk of postoperative delirium in surgical patients (risk ratio = 0.36; 95% confidence interval = 0.28-0.46).
“The overall incidence of delirium was significantly lower in patients treated with intranasal insulin (risk ratio = 0.36; 95% confidence interval = 0.28-0.46; p < 0.001).”
Insulin is linked with a higher risk of hypoglycemia in humans (patients aged over 65 on insulin versus sulfonylureas) (34% vs 5% with more than one documented episode (sulphonylurea); 2% metformin-only; p<0.001).
“27/79(34%) insulin-treated patients had >1 documented hypoglycaemia episode, compared to 4/85(5%) sulphonylurea-treated patients”
Humanspatients aged over 65 on insulin versus sulfonylureasn = 79
Insulin raises the risk of hypoglycemia in silico (modeled drug-induced hypoglycemia) (8.64 events per person-year (65-79 years); 12.06 events per person-year (80 years and older)).
“Incidence rates of drug-induced hypoglycemia were the highest for basal insulin and sulfonylureas”
Insulin is associated with sarcopenia in humans (Type 2 diabetes mellitus for at least 12 months; multivariable analysis) (aOR 0.081, 95% CI 0.010–0.649).
“whereas insulin use was inversely associated (aOR 0.081, 95% CI: 0.010–0.649; p = 0.018).”
HumansType 2 diabetes mellitus for at least 12 months; multivariable analysisn = 100
Insulin is linked with a higher risk of sarcopenia in male patients with T2DM.
“decreased serum albumin (Alb), elevated alkaline phosphatase, and insulin use were also significant risk factors for sarcopenia in male patients with T2DM.”
Insulin lowers the risk of postoperative cognitive dysfunction in humans after laparoscopic radical resection of colorectal cancer (4(13.3%) vs. 12 (38.7%)).
“The insulin group had a significantly lower POCD rate compared with the control group at postoperative day 7 [4(13.3%) vs. 12 (38.7%), p = 0.024].”
Human trialafter laparoscopic radical resection of colorectal cancerpostoperative 7 daysn = 61
Insulin lowers the risk of postoperative cognitive dysfunction in humans (metabolic syndrome undergoing noncardiac surgery) (20.8% vs 45.1% (P = 0.008)).
“POCD occurred in the insulin group on the 7th postoperative day in 11 (20.8%) patients, which was fewer than the 23 (45.1%) patients in the placebo group (P = 0.008).”
Human trialmetabolic syndrome undergoing noncardiac surgery40 IU7 daysn = 116
Insulin is associated with frailty in older adults with type 2 diabetes.
“Frailty levels were significantly higher among women, those with lower education, longer disease duration, insulin or OAD+insulin users, and individuals with complications.”
The Journal of clinical endocrinology and metabolism·
Insulin is linked with a higher risk of bone fracture in humans (adjusted for fracture risk factors and diabetes-related comorbidities) (HR 1.10 (95% CI 1.07-1.12)).
“Use of insulin was independently associated with greater risk of fracture (HR = 1.10, 95% CI 1.07-1.12).”
Humansadjusted for fracture risk factors and diabetes-related comorbiditiesmalesn = 652,901
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·
Insulin is associated with bone fracture in humans (type 2 diabetes).
“Several diabetes-related factors are associated with increased fracture risk, including exogenous insulin therapy, vascular complications, and poor glycaemic control”
Insulin is linked with a higher risk of hip fracture in patients with type 2 diabetes.
“Thiazolidinediones and insulin use are factors with the greater magnitude of strength of association among those significantly associated with hip fracture.”
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·
Insulin is associated with hip fracture in humans (Patients with type 2 diabetes).
“In patients with diabetes, significant csHRs for incident hip fracture were male sex (protective), body mass index (protective), insulin use, and renal impairment.”
HumansPatients with type 2 diabetesMean 14.1 yearsn = 1,291
Insulin is associated with FFA-palmitate Ra suppression by niacin in upper-body obesity and/or type 2 diabetes mellitus (r = -0.93, P < 0.001).
“The suppression of FFA-palmitate Ra by insulin on the saline control day and by niacin after an overnight infusion were highly correlated (r = -0.93, P < 0.001).”
Human trialin upper-body obesity and/or type 2 diabetes mellitusadipose tissuen = 10
Henagliflozin decreases insulin in severely hyperglycaemic T2DM patients.
“The TAR, insulin dosage, mean glucose (MG) and glucose management indicator (GMI) in the henagliflozin+CSII group were significantly lower than those in the CSII group.”
Human trialin severely hyperglycaemic T2DM patients7-dayn = 210
Enrollment closed before the planned 36 eyes were reached because of the limited number of eligible patients and the long recruitment period (July 2024 to December 2025); 20 eyes of 19 participants were enrolled.
Protocol was terminated due to enrollment + feasibility issues. Aim 2 not conducted. Aims 1 + 3 were conducted in part. During Aim 3 the IRB requested that the study be transitioned under a new protocol (2018-9208) in order to simplify reporting.
Who is developing insulin?
3 companies: Pfizer, Tanabe Pharma and Astellas Pharma.
Independent labs report that insulin increases senescence in human cells but decreases it in mice; human trials report less postoperative delirium with intranasal administration but impaired verbal episodic memory during insulin stimulation. Three registered trials concern aging; across uses, 80 ended over a year ago without posted results or citing papers. Authors declare company ties, and developers sponsor some trials.
Intranasal insulin lowers postoperative delirium risk in human trials; independent labs report improved spatial memory in rats and increased hypoglycemia in humans, but an aged-rat study shows no clear memory effect. Three registered trials concern aging; across uses, 80 trials ended over a year ago without posted results or citing papers. Authors declare developer ties; developers sponsor 32 of 213 trials across uses.
Summary rewritten as its findings changed.
As it read before
Human trials report less postoperative delirium with intranasal insulin; independent labs reproduce increased hypoglycemia risk in humans and spatial-memory improvements in rats, alongside a rat study reporting no spatial-memory effect. Three registered trials concern aging; 80 across uses ended over a year ago without posted results or citing papers. Developers sponsor 32 trials, and human papers declare developer ties.
Summary rewritten as its findings changed.
As it read before
Human research links insulin to mortality in cancer with predominantly concomitant type 2 diabetes, and vascular dementia in type 2 diabetes versus metformin alone; dapagliflozin and semaglutide reduce insulin. Work spans four independent labs in four countries; 80 trials ended over a year ago without posted results or citing papers, and developers sponsor 31 of 211 registered trials.
A randomized crossover trial in eight healthy men averaging 68 years old found that muscles could directly take up galactose, a sugar.A randomized crossover trial in eight healthy men averaging 68 years old found that muscles could directly take up galactose, a sugar.
Muscle models grown from human donor cells showed gene activity responses to electrical stimulation that overlapped with responses in those donors’ muscles after…Muscle models grown from human donor cells showed gene activity responses to electrical stimulation that overlapped with responses in those donors’ muscles after exercise.
Who was studiedHuman skeletal muscle organoids from donor myoblasts, 2h
What changedExercise-responsive gene activity rose in electrically stimulated versus unstimulated muscle organoids, paralleling donors’ muscle responses to exercise
The catchElectrical stimulation substitutes for exercise, without blood flow, hormonal dynamics, or immune interactions